Hemispherx Biopharma Class Action Settlement Announced In Securities Class Action Lawsuit Pending Against Hemispherx Biopharma Over Ampligen.
A class action settlement has reportedly been reached in a class action lawsuit against Hemispherx Biopharma (“Hemispherx Biopharma” or “HEB” or “Defendant”) pending in the United States District Court for the Eastern District of Pennsylvania, alleging, among other things that Hemispherx Biopharma, a biotechnology company, and certain Hemispherx Biopharma officers misrepresented the status of Hemispherx’s new drug application for Ampligen, an experimental treatment for chronic fatigue syndrome, purportedly in violation of federal securities laws, according to a Hemispherx Biopharma class action settlement news report.
If You Have Thoughts On The Hemispherx Biopharma Class Action Lawsuit Settlement, Share Your Class Action Settlement Comments Below.
What is the status of this class action law suit? I bought on the companys public news that the new drug met the criteria for approval and it didn’t. I sent emails to law offices about a week after the drug was denied approval and was told that I would be contacted latter and grouped into a pool of other people who bought on this false news.
Still waiting on some type of response from any law firm or HEB but starting to have my doubts.